BRIEF-Sana Biotechnology Announces Increased Focus On Type 1 Diabetes And B-Cell Mediated Autoimmune Diseases With The Potential To Deliver Clinical Proof Of Concept Data Across Multiple Studies In 2024 And 2025

Reuters
2024-11-05

Nov 4 (Reuters) - Sana Biotechnology Inc :

* SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON TYPE 1 DIABETES AND B-CELL MEDIATED AUTOIMMUNE DISEASES WITH THE POTENTIAL TO DELIVER CLINICAL PROOF OF CONCEPT DATA ACROSS MULTIPLE STUDIES IN 2024 AND 2025

* SANA BIOTECHNOLOGY INC - TO PRIORITIZE SC291 IN B-CELL MEDIATED AUTOIMMUNE DISEASES

* SANA BIOTECHNOLOGY INC - SUSPENDS DEVELOPMENT OF SC291 IN ONCOLOGY AND SC379

* SANA BIOTECHNOLOGY INC - 2024 OPERATING CASH BURN MAY EXCEED $200 MILLION

* SANA BIOTECHNOLOGY INC - HALTS ENROLLMENT IN SC291 ONCOLOGY TRIAL

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10